Dark

Check out our Dark Pool Levels

EYEN
Eyenovia, Inc. Common Stock
stock NASDAQ

Inactive

Jul 2, 2025

15.82USD+49.811%(+5.26)4,643,575

Pre-market

0.00USD-100.000%(-10.56)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 17, 2021

09:36AM EST Eyenovia Form 4 Filing Shows 10% Owner Stuart Grant Purchased 100K Shares At Average Price Of $3.45/Share Benzinga

Nov 10, 2021

05:42PM EST Eyenovia Q3 EPS $(0.21) Beats $(0.23) Estimate Benzinga

08:23AM EST Eyenovia Sponsored Study Titled 'Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults (VISION-2)' Posted To ClinicalTrials.gov Website; Study Is Recruiting Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 8, 2021

08:00AM EST Eyenovia to Participate in Myopia Panel Discussion at the GlobeNewswire Inc

Nov 5, 2021

03:25PM EDT Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released on Thursday, November 11, after the close. GlobeNewswire Inc

Nov 4, 2021

08:19AM EDT Eyenovia Reports First Patient Enrolled In Phase 3 VISION-2 Trial Of MicroLine For Presbyopia Benzinga

08:00AM EDT Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022 GlobeNewswire Inc

07:35AM EDT 4 Penny Stocks Insiders Are Buying Benzinga

05:12AM EDT Eyenovia CEO Tsontcho Ianchulev Reported Purchase of 30,000 Shares @ Avg Price of $4.04/Share in Form 4 Filing on Wednesday Benzinga

Nov 1, 2021

03:23PM EDT Pomerantz LLP is investigating claims on behalf of investors of Eyenovia, Inc. (Eyenovia or the Company) (NASDAQ: EYEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 25, 2021

04:20PM EDT Eyenovia 8-K Shows Co. Sees Reporting ~$21.4M In Cash, Cash Equivalents As Of Sept. 30, 2021 Benzinga

02:31PM EDT Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; Bakkt Holdings Shares Spike Higher Benzinga

12:12PM EDT Mid-Day Market Update: Crude Oil Rises Over 1%; ERYTECH Pharma Shares Plummet Benzinga

10:17AM EDT Mid-Morning Market Update: Markets Edge Higher; Kimberly Clark Cuts FY21 Forecast Benzinga

08:03AM EDT Eyenovia Announces Reclassification Of MydCombi As Drug-Device Combination Product By FDA Benzinga

08:00AM EDT Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers GlobeNewswire Inc

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 5, 2021

12:55PM EDT Eyenovia Has Filed For FCC ID Approval On EYENOVIAGEN1 Optejet Base G1. Benzinga

Oct 1, 2021

02:29PM EDT Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates Benzinga

Sep 27, 2021

12:35PM EDT Eyenovia's Return On Capital Employed Insights Benzinga

Sep 23, 2021

10:06AM EDT Eyenovia Files Patent Application Titled 'OPHTHALMIC DRUG DELIVERY' Benzinga

Aug 11, 2021

04:45PM EDT Eyenovia Q2 EPS $(0.19) Beats $(0.23) Estimate Benzinga

04:05PM EDT Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia GlobeNewswire Inc

09:06AM EDT Earnings Scheduled For August 11, 2021 Benzinga

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

04:27AM EDT Earnings Scheduled For August 11, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

08:00AM EDT Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11 GlobeNewswire Inc

Jul 7, 2021

04:01PM EDT Eyenovia to Participate in Two Upcoming Investor Conferences GlobeNewswire Inc

Jun 15, 2021

08:09AM EDT Eyenovia Provides Corporate Update On Its Pipeline RTTNews

08:03AM EDT Eyenovia Provides Corporate Update; Highlights Progress In Phase 3 Programs And Previously-Disclosed Licensing Agreements Benzinga

08:00AM EDT Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics, today provided a corporate update on its pipeline with recent and upcoming milestones. GlobeNewswire Inc

May 28, 2021

08:41AM EDT EyeNovia National Institutes For Health ClinicalTrials.gov Study Record For Co.'s 'A Phase 4 Study Evaluating Pupil Dilation Speed With the MAP Dispenser (SPEED)'; Shows Study Is Recruiting Benzinga

May 25, 2021

11:19AM EDT Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia Study Benzinga

10:13AM EDT Shares of Eyenovia, Inc. (EYEN) are rising more than 10% Tuesday morning after the company announced positive top line results from the late-stage study of MicroLine for the treatment of Presbyopia. RTTNews

09:05AM EDT Eyenovia Reports Topline Results From VISION-1 Phase 3 Study Of MicroLine For Treatment Of Presbyopia Met Primary Endpoint Benzinga

09:04AM EDT Primary endpoint was achieved with well-tolerated micro-array print (MAP) safety profile GlobeNewswire Inc

May 12, 2021

04:25PM EDT Eyenovia Q1 EPS $(0.21) Beats $(0.22) Estimate Benzinga

04:05PM EDT Eyenovia Reports First Quarter 2021 Financial Results GlobeNewswire Inc

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

04:22AM EDT Earnings Scheduled For May 12, 2021 Benzinga

May 10, 2021

08:30AM EDT Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics, today announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB). GlobeNewswire Inc

May 5, 2021

08:00AM EDT Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12 GlobeNewswire Inc

Apr 1, 2021

06:47AM EDT HC Wainwright & Co. Maintains Buy on Eyenovia, Raises Price Target to $8 Benzinga

Mar 25, 2021

04:15PM EDT Eyenovia Q4 EPS $(0.17) Beats $(0.21) Estimate Benzinga

04:05PM EDT Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire Inc

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

04:03AM EDT Earnings Scheduled For March 25, 2021 Benzinga

Mar 18, 2021

08:00AM EDT Eyenovia to Report Fourth Quarter and Full Year 2020 Results on GlobeNewswire Inc

Mar 17, 2021

08:27AM EDT Eyenovia Announces Publication Of MIST Pivotal Studies, Says Demonstrates Efficacy, Safety Of MAP Fixed-Combination Tropicamide-Phenylephrine Product For Mydriasis Benzinga

Mar 10, 2021

08:00AM EST Eyenovia to Participate in the 33rd Annual Roth Conference GlobeNewswire Inc

Mar 2, 2021

07:41AM EST Eyenovia Announces FDA Acceptance of the MydCombi NDA Benzinga

Feb 16, 2021

08:00AM EST Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics, today announced that it will host a Key Opinion Leader (KOL) webinar, entitled: Presbyopia in Focus: Unlocking one of the Biggest Market Opportunities in Ophthalmology, on Monday, February 22, 2021 at 1:00pm Eastern Time. GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Jan 13, 2021

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

Jan 12, 2021

08:16AM EST The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga

Jan 6, 2021

08:00AM EST Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics, today announced that Dr.Sean Ianchulev, Chief Executive Officer and Chief Medical Officer, will participate in a panel discussion on presbyopia at the upcoming LifeSci Partners 10th Annual Corporate Access Event. GlobeNewswire Inc

Dec 29, 2020

07:18AM EST Eyenovia, Inc. (EYEN) has submitted a New Drug Application to the U. S. FDA for MydCombi, a fixed combination pupil dilation agent. The NDA submission was based on the MIST-1 and MIST-2 studies. The NDA submission follows the initial enrollment of the VISION-1 study, phase 3 study for MicroLine in presbyopia, with top-line data expected the first half of 2021. RTTNews

07:11AM EST Eyenovia Submits NDA To FDA For MydCombi RTTNews

07:03AM EST Eyenovia Submits New Drug Application To FDA For Pharmacologic Mydriasis With MydCombi Benzinga

Dec 26, 2020

09:16AM EST The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks Benzinga

Dec 16, 2020

07:06AM EST Eyenovia Announces First Patients Enrolled In Phase 3 Study Of MicroLine For Presbyopia Benzinga

Nov 10, 2020

04:41PM EST Eyenovia Q3 EPS $(0.23) Misses $(0.18) Estimate Benzinga

04:06PM EST Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics, today reported its financial results for the third quarter ended September 30, 2020. GlobeNewswire Inc

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 23, 2020

09:36AM EDT HC Wainwright & Co. Maintains Buy on Eyenovia, Lowers Price Target to $6 Benzinga

Oct 14, 2020

08:47AM EDT Roth Capital Maintains Buy on Eyenovia, Lowers Price Target to $11 Benzinga

Oct 13, 2020

07:00AM EDT Company reaffirms near term milestones for the Mydcombi (MicroStat) NDA and the MicroLine presbyopia program Phase III results GlobeNewswire Inc

Oct 12, 2020

07:12AM EDT Bausch Health Acquires License For Investigational RTTNews

07:09AM EDT Eyenovia's Treatment for Pediatric Myopia Progression Licensed by Bausch Health for Development and Commercialization in the US and Canada, Eyenovia to Receive $10M Upfront and Up to $35M in Milestone Payments Benzinga

07:02AM EDT Bausch Health Licenses Eyenovia's Investigational Treatment For Reduction Of Pediatric Myopia Progression In Children RTTNews

07:01AM EDT Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction PR Newswire

Sep 25, 2020

01:44PM EDT Eyenovia Director Grant Buys 75,000 @ Avg Price: $2.99 Benzinga

Sep 9, 2020

08:30AM EDT Eyenovia to Present at the 22nd Annual H.C. Wainwright Global GlobeNewswire Inc

Aug 24, 2020

08:30AM EDT Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics, today announced that the underwriters of its previously announced public offering of common stock have fully exercised their option to purchase an additional 500,000 shares at the public offering price of $3.60 per share. GlobeNewswire Inc

Aug 21, 2020

04:05PM EDT Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics, today announced the closing of its previously announced underwritten public offering of 3,333,334 shares of its common stock at a price to the public of $3.60 per share. GlobeNewswire Inc

Aug 19, 2020

09:31AM EDT Eyenovia Prices Public Offering Of 3.33 Mln Shares At $3.60/Shr RTTNews

09:11AM EDT Eyenovia Prices Public Offering Of 3.333M Shares At $3.60/Share Benzinga

09:10AM EDT Eyenovia, Inc. Prices Public Offering of Common Stock GlobeNewswire Inc

Aug 18, 2020

04:03PM EDT Eyenovia, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

04:03PM EDT Eyenovia, Inc. Announces Proposed Public Offering of Common Stock; No Terms Disclosed Benzinga

Aug 17, 2020

09:05AM EDT What To When You Start The Day In The Red Benzinga

Aug 13, 2020

08:18AM EDT The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller Benzinga

06:58AM EDT HC Wainwright & Co. Maintains Buy on Eyenovia, Raises Price Target to $7 Benzinga

Aug 12, 2020

04:15PM EDT Eyenovia Q2 EPS $(0.25), Inline Benzinga

04:05PM EDT Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics, today reported its financial results for the second quarter ended June 30, 2020. GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 12, 2020 Benzinga

Aug 11, 2020

04:45PM EDT 04:45 Tuesday, August 11, 2020 RTTNews

12:11PM EDT Mid-Day Market Update: Gold Plunges Over 4%; Pfenex Shares Spike Higher Benzinga

10:30AM EDT Mid-Morning Market Update: Markets Mostly Higher; SYSCO Reports Q2 Loss Benzinga

10:18AM EDT Shares of Eyenovia Inc. (EYEN) are gaining more than 57 percent or $2.09 in Tuesday's morning trade at $5.73, after touching a new 52-week high of $6.92 as the ophthalmic biopharmaceutical company announced a collaboration and license deal with Arctic Vision. RTTNews

08:07AM EDT Eyenovia, Arctic Vision Announce Exclusive Collaboration And License Agreement RTTNews

08:00AM EDT Eyenovia Eligible to Receive up to a Total of $45.75 million in Upfront Payments and Development and Commercialization Milestones and Development Costs GlobeNewswire Inc

Jul 29, 2020

08:30AM EDT Eyenovia Announces Conference Call and Webcast for Second Quarter GlobeNewswire Inc

Share